Article Text

Download PDFPDF
Palliative treatment of chronic breathlessness syndrome: the need for P5 medicine
  1. Daisy J A Janssen1,2,
  2. Miriam J Johnson3
  1. 1 Department of Research and Development, CIRO, Horn, The Netherlands
  2. 2 Department of Health Services Research, CAPHRI School for Public Health and Primary Care, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
  3. 3 Wolfson Palliative Care Research Centre, University of Hull, Hull, UK
  1. Correspondence to Dr Daisy J A Janssen, Research & Development, CIRO, Horn 6085 NM, The Netherlands; daisyjanssen{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the editor,

Breathlessness is the most frequently reported symptom by patients with advanced chronic lung disease or chronic heart failure and has widespread consequences.1 Despite optimal treatment for the underlying disease, disabling breathlessness persists for many—recently named chronic breathlessness syndrome.2 Patients, and their families, may live with chronic breathlessness for years, with serious functional and social limitations, care dependency and anxiety.3 Clinical practice guidelines and policy statements now highlight pharmacological and non-pharmacological interventions for the palliative management of breathlessness as a cornerstone of care.4 5 Despite this, many clinicians still feel ill-equipped and under-resourced to manage breathlessness, which remains a neglected symptom.1 6

Although the evidence base for breathlessness interventions is growing, important questions concerning optimal palliative management of breathlessness remain.7 Studies of opioids are mostly small and of cross-over design. The most recent Cochrane review8 found a smaller effect size and lower precision than other authors, although a repeat analysis9 of the same studies accounting for the cross-over design of most showed a larger effect size with improved precision and benefit consistent with a clinically relevant improvement.10 Safety concerns appear unfounded with oral low-dose opioid. Indeed, national cohorts of oxygen-dependent COPD and advanced interstitial lung disease found no association with excess hospital admission or mortality.11 12 Another very large cohort of people with COPD showed a statistically significant, small absolute excess mortality but data regarding reason for prescribing (eg, pain or breathlessness) was not available making clinical interpretation difficult.13 A systematic review …

View Full Text


  • Contributors Both authors had substantial contributions to the conception or design of the work; drafting the work and revising it critically for important intellectual content; final approval of the version published. Both authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests DJAJ reports personal fees from Boehringer Ingelheim, personal fees from Novartis, and personal fees from AstraZeneca, outside the submitted work. MJJ is clinical consultant for Mayne Pharma for which the University of Hull received payment.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles